Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 5/20 | 0.40 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.40 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | KCNB1 | Q14721 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12444347 | 0.96 | ERAP2 (0.43) | ERAP2LNPEPFFAR1ERAP1LTA4H | |
| SCHEMBL10199137 | 0.96 | ERAP2 (0.43) | ERAP2LNPEPFFAR1ERAP1LTA4H | |
| SCHEMBL10199226 | 0.96 | ERAP2 (0.43) | ERAP2LNPEPFFAR1ERAP1LTA4H | |
| SCHEMBL12444349 | 0.96 | ERAP2 (0.43) | ERAP2LNPEPFFAR1ERAP1LTA4H | |
| SCHEMBL19219773 | 0.95 | ERAP2 (0.42) | ERAP2LNPEPFFAR1ERAP1LTA4H | |
| SCHEMBL21371614 | 0.95 | ERAP2 (0.42) | ERAP2LNPEPFFAR1ERAP1LTA4H | |
| SCHEMBL21371982 | 0.95 | ERAP2 (0.42) | ERAP2LNPEPFFAR1ERAP1LTA4H | |
| SCHEMBL13978374 | 0.94 | MMP2 (0.41) | ERAP2LNPEPFFAR1ERAP1LTA4H | |
| SCHEMBL13978361 | 0.93 | ERAP2 (0.41) | ERAP2LNPEPFFAR1ERAP1LTA4H | |
| SCHEMBL15138936 | 0.89 | ERAP2 (0.47) | ERAP2LNPEPERAP1LTA4HSUV39H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120258141-A9 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258141-A9 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120039945-A1 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120039945-A1 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258141-A9 | Methods Of Immune Modulation | IFNG, CD14, TLR3 | ERAP2 1201/4885LNPEP 922/4885FFAR1 1192/4885 |
| US-20120039945-A1 | Methods Of Immune Modulation | IFNG, CD14, TLR3 | ERAP2 1201/4885LNPEP 922/4885FFAR1 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.